Myocardial regeneration: Present and future trends

被引：21

作者：

Etzion S. ^{[1
,2
]}

Kedes L.H. ^{[3
,4
]}

Kloner R.A. ^{[4
,5
]}

Leor J. ^{[1
,6
]}

机构：

[1] Neufeld Cardiac Research Institute, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer

[2] Cardiac Research Center, Ben-Gurion University, Beer-Sheva

[3] Institute for Genetic Medicine, Department of Biochemistry and Molecular Biology, Los Angeles

[4] Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles

[5] Heart Institute, Good Samaritan Hospital, Los Angeles

[6] Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer

来源：

American Journal of Cardiovascular Drugs | 2001年 / 1卷 / 4期

基金：

以色列科学基金会;

关键词：

Mesenchymal Stem Cell; Embryonic Stem Cell; Genetic Modulation; Sarcoplasmic Reticulum; Satellite Cell;

D O I：

10.2165/00129784-200101040-00002

中图分类号：

学科分类号：

摘要：

Cardiomyocytes are terminally differentiated and are unable to proliferate in response to injury. Genetic modulation, cell transplantation and tissue engineering promise a revolutionary approach for myocardial regeneration and tissue repair after myocardial injury. Current data derived from animal models suggest that it may be possible to treat heart failure by inserting genetic materials or myogenic cells into injured myocardium. Success with animal models has raised the hope for new treatment after heart attacks and could prove an alternative to transplantation, particularly in elderly patients for whom there is often a lack of donor hearts. This exciting research, however, still faces significant difficulties before it can develop into a clinical therapeutic tool and many challenges need to be overcome before cell transplantation, gene therapy and tissue engineering can be considered efficient, therapeutic strategies for myocardial regeneration. © Adis International Limited All rights reserved.

引用

页码：233 / 244

页数：11

共 110 条

[1] Sharpe N., Doughty R., Epidemiology of heart failure and ventricular dysfunction, Lancet, 352, 1 SUPPL., (1998)
[2] Massie B.M., Shah N.B., Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management, Am Heart J, 133, pp. 703-712, (1997)
[3] Hoes A.W., Mosterd A., Grobbee D.E., An epidemic of heart failure? Recent evidence from Europe, Eur Heart J, 19, SUPPL. L, (1998)
[4] Cleland J.G., Khand A., Clark A., The heart failure epidemic: Exactly how big is it?, Eur Heart J, 22, pp. 623-626, (2001)
[5] Swedberg K., Kjekshus J., Snapinn S., Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS i, Eur Heart J, 20, pp. 136-139, (1999)
[6] Mann D.L., Mechanisms and models in heart failure: A combinatorial approach, Circulation, 100, pp. 999-1008, (1999)
[7] Reinlib L., Field L., Cell transplantation as future therapy for cardiovascular disease?: A workshop of the national heart lung and blood institute, Circulation, 101, (2000)
[8] Kessler P.D., Byrne B.J., Myoblast cell grafting into heart muscle: Cellular biology and potential applications, Annu Rev Physiol, 61, pp. 219-242, (1999)
[9] Soonpaa M.H., Koh G.Y., Klug M.G., Et al., Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium [see comments], Science, 264, pp. 98-101, (1994)
[10] Koh G.Y., Kim S.J., Klug M.G., Et al., Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis, J Clin Invest, 95, pp. 114-121, (1995)

← 1 2 3 4 5 6 7 8 9 10 →